Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic
- 28 January 2026
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (2) , 728-745
Abstract
Background: Subjective cognitive decline (SCD) represents the first early symptomatic stage of Alzheimer's disease (AD). Objective: We aimed to investigate the relationships between features in SCD and to assess the importance of these features in the future development of dementia to inform a targeted management protocol. Methods: 440 SCD patients underwent neurological and neuropsychological assessments, MRI scans, APOE genotyping, and AD biomarker evaluations. Patients were followed for a median of 10 years. Relationships among features were first assessed univariately, focusing on differences across stratified subgroups. To capture multivariate associations, we applied network analysis using a Markov Random Field. Finally, baseline features were related to dementia progression using an XGboost machine learning model. Results: Women comprising 68.9% of the cohort, were generally younger at onset, had lower APOE ε4 prevalence, and differed in neuropsychological performance compared to men. Older patients (age >60) exhibited a higher prevalence of APOE ε4 and cerebral small vessel disease. Patients with depressive symptoms demonstrated lower cognitive performance across multiple domains. Network analysis indicated complex interconnections among gender, cognitive reserve, SCD severity, and depressive symptoms. The XGboost model achieved 74% accuracy in predicting progression to dementia, identifying age at onset, mini-mental state examination scores, and APOE genotype as the most predictive factors. Conclusions: This study highlights the role of age, gender, APOE genotype, and depressive symptoms in the presentation and progression of cognitive decline. By identifying key predictive features, we propose a personalized management protocol aimed at optimizing care for individuals with SCD. Trial registration number: NCT05569083, registration date: 2019-05-30Keywords
Funding Information
- Regione Toscana (D18D20001300002)
- American Academy of Neurology (2024 Robert Katzman Award)
This publication has 63 references indexed in Scilit:
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- A comparative analysis of gradient boosting algorithmsArtificial Intelligence Review, 2020
- Demographic characteristics and neuropsychological assessments of subjective cognitive decline (SCD) (plus)Annals of Clinical and Translational Neurology, 2020
- The dual role of cognitive reserve in subjective cognitive decline and mild cognitive impairment: a 7-year follow-up studyJournal of Neurology, 2019
- Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sampleAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2017
- The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive DisorderCNS Drugs, 2015
- Are memory complaints predictive for dementia? A review of clinical and population-based studiesInternational Journal of Geriatric Psychiatry, 2000
- ApoE allele frequencies in Italian sporadic and familial Alzheimer's diseaseNeuroscience Letters, 1994
- Memory Complaints in Older AdultsArchives of Neurology, 1991
- Memory Complaints and Impairment in Normal, Depressed, and Demented Elderly Persons Identified in a Community SurveyArchives of General Psychiatry, 1990